Avadel Pharmaceuticals PLC (NAS:AVDL)
$ 11.17 0.02 (0.18%) Market Cap: 1.08 Bil Enterprise Value: 1.01 Bil PE Ratio: 0 PB Ratio: 14.41 GF Score: 40/100

Avadel Pharmaceuticals PLC at Oppenheimer Healthcare Conference (Virtual) Transcript

Mar 17, 2022 / 02:40PM GMT
Release Date Price: $7.32 (+4.13%)
Frank Brisebois
Oppenheimer & Co. - Analyst

Great. Well, thanks, everyone, for joining today on day three of the Oppenheimer healthcare conference. Still virtual but hopefully we're kind of on the back end of that side. So, I'm Frank Brisebois; I'm one of the biotech analysts at the firm. It's my pleasure to introduce Avadel Pharmaceuticals. The ticker is AVDL. We do cover the stock at an outperform rating at the firm, and they are focused on narcolepsy.

Here -- we'll go over it in depth, but the story is it's a once nightly sodium oxybate [trying] to enter an already established blockbuster market, but they did have a PDUFA date. And I don't think we can have this chat without talking about it, Greg. And I'm sorry; I'm sure you've talked about it plenty. But more questions to come here.

So, the PDUFA date was October 15 and we've been waiting on the FDA. And it seems like nothing really on Avadel's side much here. But we'll go into the details of what's going on there. They also just announced their earnings this morning and it seems like they had recent FDA interaction. So, all

Already have an account? Log in
Get the full story
Access to All Earning Calls and Stock Analysis
30-Year Financial on one screen
All-in-one Stock Screener with unlimited filters
Customizable Stock Dashboard
Real Time Insider Trading Transactions
8,000+ Institutional investors’ 13F holdings
Powerful Excel Add-in and Google sheets Add-on
All data downloadable
Quick customer support
And much more...
30-Day 100% money back guarantee
You are not charged until the trial ends. Subscription fee may be tax deductible.
Excellent
4.6 out of 5 Trustpilot